Table 1.
Interaction between GBV-C viremia and interleukin 2 (IL-2) assignment for CD4 change
| Treatment Group | IL-2 vs no IL-2 ‡ | IV IL-2 vs SC IL-2 | |||
|---|---|---|---|---|---|
| Week 60 – week 12 | IV IL-2 (n) | SC IL-2 (n) | No IL-2 (n) | ||
| GBV-C neg | *859 (10) | *299 (18) | *62 (18) | †437 (p<10−5, 257 to 617) | †560 (p<10−6, 362 to 758) |
| GBV-C pos | *180 (13) | *106 (9) | *108 (9) | †42 (p=0.73, −194 to 278) | †74 (p=0.50, −144 to 291) |
| GBV-C Neg vs Pos | p<10−7 | p=0.06 | P=0.71 | §†395 (p=0.01, 98 to 692) | §†486 (p=0.002, 193 to 781) |
| Week 84-week 12 | IV IL-2 (n) | SC IL-2 (n) | No IL-2 (n) | ||
| GBV-C neg | *1273 (10) | *395 (18) | *126 (17) | †582 (p<10−4, 327 to 837) | †878 (p<10−7,619 to 1137) |
| GBV-C pos | *226 (14) | *207 (9) | *148 (9) | †71 (p=0.67, −255 to 397) | †19 (p=0.89, −262 to 299) |
| GBV-C Neg vs Pos | p<10−9 | p=0.17 | P=0.90 | §†511 (p=0.02, 97 to 926) | §†860 (p<10−4, 478 to 1241) |
*
Change in CD4 count. IV = intravenous IL-2 = interleukin 2, SC = subcutaneous. GBV-C positive (negative) = GBV-C RNA detected (not detected) in plasma as described in the methods.
†
CD4 change from week 12 analyzed as a linear model.
‡
the two IL-2 treatment groups (IV and SC) are pooled. For the IV vs SC comparison, three treatment groups were used and the contrast between IV and SQ estimated.
§
Interaction tests are based on likelihood ratio tests and are the interaction of the difference between treatment groups with GBV-C viremia.